NCR201
/ Nuwacell Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
June 02, 2026
Robot-assisted transplantation of hypoimmune iPSC derived dopaminergic progenitor cells for idiopathic Parkinson’s disease
(WPC 2026)
- P1 | "Conclusions This clinical result demonstrated that in 7 idiopathic PD patients the NCR201 cell replacement therapy achieved functional engraftment, leading to rapid, substantial, and sustained improvements in both motor and non-motor symptoms. As the first hypoimmune iDAPs product entering clinical trial, these findings showed early promise of NCR201 as a transformative treatment for PD."
Late-breaking abstract • CNS Disorders • Movement Disorders • Parkinson's Disease • Transplantation • FOXA2
June 02, 2026
Robot-assisted Transplantation of hypoimmune iPSC derived dopaminergic progenitor cells for PRKN associated early-onset Parkinson's disease: A case report
(WPC 2026)
- "The close correlation between clinical improvement and restored dopaminergic neural innervation presents a prove of concept for NCR201 cell replacement therapy in PRKN-PD intervention. These preliminary findings warrants an expanded study involving more inherited PD patients with long-term observation."
Case report • Clinical • Late-breaking abstract • CNS Disorders • Movement Disorders • Parkinson's Disease • Transplantation • FOXA2
May 20, 2026
China ‘outpacing the US’ in biotech race to find cure for Parkinson’s disease
(South China Morning Post)
- "According to Nuwacell, its candidate also appears to trigger less immune rejection following transplant, allowing the cells to survive longer after being implanted into the brain...Follow-up data from its longest-tracked patients showed that increased dopamine function in the brain had been maintained for more than 18 months without decline...According to Shi, all six patients recruited for the trial – which started in the middle of last year – showed rapid improvements in motor control, alongside significant and sustained increases in dopamine signalling in the brain...Nuwacell’s co-founder and chief technology officer Zhang, who holds a PhD from Cornell University, said that in the 12 months from April last year, the company had enrolled nearly 40 patients."
P1 data • Trial status • Parkinson's Disease
August 02, 2025
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Nuwacell Biotechnologies Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease
May 19, 2025
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Nuwacell Biotechnologies Co., Ltd.
New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
1 to 5
Of
5
Go to page
1